Biohaven

Biohaven EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Biohaven (BHVN) as of Nov 21, 2026 is -2.58. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -1.98 — a change of 30.13% (lower).

EV/FCF

-2.58

YoY

30.13%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Biohaven is 2025 -2.58 . EV/FCF (Enterprise Value to Free Cash Flow) of Biohaven was 2024 -1.98 . It decreases by 30.13% lower compared to the previous year.

The Biohaven EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-7.46 USD
Jan 1, 2019
-4.15 USD
Jan 1, 2020
-2.09 USD
Jan 1, 2021
-2.37 USD
Jan 1, 2022
-3.50 USD
Jan 1, 2023
-3.79 USD
Jan 1, 2024
-1.98 USD
Jan 1, 2025
-2.58 USD
The Biohaven EV/FCF history
YEAREV/FCFYoY
-2.58+30.13%
-1.98-47.61%
-3.79+8.33%
-3.50+47.46%
-2.37+13.29%
-2.09-49.55%
-4.15-44.45%
-7.46-53.12%
-15.92-71.51%
-55.89-80.91%
-292.80-79.35%
-1,418.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

EV/FCF (Enterprise Value to Free Cash Flow) of Biohaven is -2.58 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Biohaven changed from -1.98 to -2.58, representing a 30.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Biohaven since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Biohaven with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biohaven

All Key Metrics — Biohaven